ClinicalTrials.gov
public full text
Public Domain
Nocturnal TLA for Severe Allergic Asthma After Withdrawal of Omalizumab Therapy
This is a randomized, controlled study with a 48-week treatment phase to determine the clinical efficacy of temperature controlled laminar flow device (TLA, Airsonett™) in the patients with severe allergic asthma who are withdrawal of omalizumab therapy
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- A Guideline Approach to Therapy Step-down Utilising Flutiform Change and Step-down#886558
- Study to Investigate the Effects of Melatonin, Temazepam & Zolpidem on Sleep EEG in Men and Women#1442686
- Pharmacokinetic Study of Synera in Healthy Volunteers#1113978
- Study to Assess the Use of Tezampanel for Opioid Withdrawal Syndrome in Treatment-Seeking Patients With Opioid Use Disorder#982404
- The Role of Timed Awakening in Treatment of Enuresis#1339557
Record · ID 1499343
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive